Indications for: EMTRIVA
HIV-1 infection, in combination with other antiretroviral agents.
≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
<3mos: use oral soln. 3mos–17yrs (≤33kg): use oral soln; (>33kg): 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see full labeling).
Posttreatment exacerbation of hepatitis B.
Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
Nucleoside analogue (reverse transcriptase inhibitor).
Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).
Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.
Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.